FDA confirms acceptability of remaining Phase 3 pivotal clinical trials for Palatin's PL9643 in DED
September 10th 2024The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in the fourth quarter of calendar year 2024.
Brightstar Therapeutics appoints Jared Young as new chief commercial officer
September 6th 2024Young will be aiding in expanding real-world evidence programs to promotion the adoption of Brightstar’s BrightMEM corneal allograft for the treatment of limbal stem cell deficiency and persistent epithelial defects.
Expanding the treatment arsenal in glaucoma management
August 31st 2024In this episode, four expert faculty talk about the importance of early diagnosis and treatment of thyroid eye disease. They discuss the differential diagnosis, screening tests, and the need for multidisciplinary management for these patients.